MedPath

Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

Registration Number
NCT00066170
Lead Sponsor
Jazz Pharmaceuticals
Brief Summary

This study will be conducted as a randomized, double blind, double-dummy, placebo-controlled, parallel-group trial in patients diagnosed with narcolepsy. Volunteers for this trial will be required to make 5 visits over up to 14 weeks to a participating expert physician practitioner for various sleep and narcolepsy evaluations and diaries will also be collected. Participants will take assigned medications during the course of the trial. Subjects will have a 25% probability of receiving placebo for both drugs (modafinil and Xyrem). All subject volunteers must meet criteria for narcolepsy and have evidence of daytime sleepiness. Patients will not incur any personal medical expenses due to participation in this trial. The sponsor is covering all visit costs not covered by insurance and there are some funds for patient expenses such as travel.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
231
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 4:XyremXyrem + Modafinil at established dose
Group 1.Modafinil (Placebo)Xyrem + Modafinil Placebo
Group 2:Modafinil (Placebo)Xyrem Placebo + Modafinil Placebo
Group 4:Modafinil at established doseXyrem + Modafinil at established dose
Group 1.XyremXyrem + Modafinil Placebo
Group 2:Xyrem PlaceboXyrem Placebo + Modafinil Placebo
Group 3Xyrem PlaceboXyrem Placebo + Modafinil at established dose
Group 3Modafinil at established doseXyrem Placebo + Modafinil at established dose
Primary Outcome Measures
NameTimeMethod
Daytime Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT)Baseline to Week 8

The Maintenance of Wakefulness Test consisted of four 20 minute tests of the patient's ability to remain awake in soporific conditions. The Mean change from baseline to week 8 in the average MWT number of minutes until sleep onset was the primary endpoint.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (39)

The Center for Sleep and Wake Disorders/Midwest Neurology

🇺🇸

Danville, Indiana, United States

Clinical Research Group of St. Petersburg, Inc.

🇺🇸

St. Petersburg, Florida, United States

Psychiatrische Universitatsklinik

🇩🇪

Regensburg, Germany

Neurologische Poliklinik -- Universitats Spital Zurich

🇨🇭

Zurich, Switzerland

Stanford Sleep Disorders Clinic

🇺🇸

Stanford, California, United States

ALL-TRIALS Clinical Research, LLC -- Summit Sleep Disorder

🇺🇸

Winston-Salem, North Carolina, United States

CSC Research -- Grove City Sleep Diagnostic Center

🇺🇸

Grove City, Ohio, United States

Pulmonary Associates, PA

🇺🇸

Phoenix, Arizona, United States

Pacific Sleep Medicine Services, Inc.

🇺🇸

San Diego, California, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Cincinnati Clinic & Sleep Management Institute

🇺🇸

Cincinnati, Ohio, United States

Community Research Management Associates,Inc.

🇺🇸

Cincinnati, Ohio, United States

SLEEP WALKER -- Sleep Disorders Center & Neurodiagnostics--Lung Diagnostics, Ltd.

🇺🇸

San Antonio, Texas, United States

St. Jude Medical Center -- Sleep Disorders Institute

🇺🇸

Fullerton, California, United States

Neuro-Therapeutics, Inc.

🇺🇸

Pasadena, California, United States

Community Research & Sleep Management Institute

🇺🇸

Crestview Hills, Kentucky, United States

Peoria Pulmonary Associates, Ltd

🇺🇸

Peoria, Illinois, United States

Graves Gilbert Clinic

🇺🇸

Bowling Green, Kentucky, United States

The Center for Sleep & Wake Disorders

🇺🇸

Chevy Chase, Maryland, United States

Sleep Disorders Center -- Union Hospital of Cecil County

🇺🇸

Elkton, Maryland, United States

Chest Medicine Associates DBA -- Sleep Medicine Specialists

🇺🇸

Louisville, Kentucky, United States

New Jersey Neuroscience Institute at JFK Medical Center

🇺🇸

Edison, New Jersey, United States

Washington University Sleep Center

🇺🇸

St Louis, Missouri, United States

Sleep Medicine Associates of Maryland

🇺🇸

Towson, Maryland, United States

Sleep Disorders Center of Rochester

🇺🇸

Rochester, New York, United States

Raleigh Neurology Associates

🇺🇸

Raleigh, North Carolina, United States

Capital Region Sleep Disorder Center

🇺🇸

Carlisle, Pennsylvania, United States

Strong Sleep Disorders Center

🇺🇸

Rochester, New York, United States

Lowcountry Lung and Critical Care, PA

🇺🇸

Charleston, South Carolina, United States

Lehigh Valley Hospital Sleep Disorders Center

🇺🇸

Allentown, Pennsylvania, United States

SDHRF Clinical Research Center

🇺🇸

Sioux Falls, South Dakota, United States

SleepMed of South Carolina

🇺🇸

Columbia, South Carolina, United States

Center for Sleep Medicine

🇺🇸

Lafayette Hill, Pennsylvania, United States

Sioux Valley Clinic -- Pulmonary

🇺🇸

Sioux Falls, South Dakota, United States

Sleep Disorders Center

🇺🇸

Sioux Falls, South Dakota, United States

Hopital Pitie Salpetriere -- Federation des Pathologies du sommeil

🇫🇷

Paris, Cedex 13, France

Bhupesh Dihenia, MD

🇺🇸

Lubbock, Texas, United States

Vermont Medical Sleep Disorders Center, Inc.

🇺🇸

Essex Junction, Vermont, United States

Centre du sommeil -- Hopital Gui de Chauliac

🇫🇷

Montpellier, Cedex 5, France

© Copyright 2025. All Rights Reserved by MedPath